Approval of Oral Oncolytics: 1995-2020
Sheena Ward, PharmD/MSHI Class of 2023, Natasha Olson, PharmD
Mercer University College of Pharmacy, National Community Oncology Dispensing Association, Inc.

Background
• NCODA is a patient-centered organization that aims to empower interprofessional oncology teams in the delivery of positive patient-centered outcomes.
• The treatment of cancer via oral route (tablet/capsule) is increasing in prevalence in the clinical and outpatient settings.
• Oral medications used for the treatment of cancer are both novel and challenging, which results in increased importance of provider education to ensure safe treatment for patients.

Objectives
• Investigate the growing approval of oral oncology medications.
• Distinguish years where approval of oral oncolytics increase.
• Understand the current role of oral oncolytics in the treatment of cancer and how they compare with other oncolytics.
• Demonstrate need for oral oncology support for patients and providers.

Methods
• Using information available from the National Institute of Health’s National Cancer Institute, a list of all medications with an approved indication for the treatment of cancer and its affiliated indications was compiled. The list was all-inclusive and contained medications of all routes, such as oral, intravenous, etc.
• A second list, comprised strictly of oral oncolytics, or oral medications with an approved indication for the treatment of cancer from 1995-2020 was derived from the first.
• These lists were analyzed as individuals, analyzed as comparators, and extrapolated onto one another for further analysis. This was an evaluative study and IRB approval was not required.

Discussion
• Per the NIH, there are approximately 650 medications with approved indications for the treatment of cancer.
• 123 of said medications are oral oncolytics as of 2020; rising from 11 in 2000.
• Approval of oral oncolytics has most noticeably increased since 2011, with 91.1% of oral oncolytics being approved since that time.
• From 2012-2020, six individual years accounted for the approval of at least 10 oral oncolytics.

Conclusion
• Approval rates and the volume of oral oncolytics is trending exponentially.
• In parallel with this increase, providers and patients need to be continuously educated on these medications.
• NCODA and other stakeholders of positive patient outcomes provide resources to ensure safe use of these medications in a rapidly growing market.
  ➢ PQIs- Positive Quality Interventions provided by NCODA are peer-reviewed clinical guidance documents centered around specific aspects of cancer care.
  ➢ OCE Sheets- Oral Chemotherapy Education Sheets satisfy a need for clear concise unbranded education tools.
  ➢ Cost Avoidance/Waste Tracker- Tracks cost and waste of prescribed drug therapies.
  ➢ Patient Satisfaction Survey- Aims to collect the information that matters most to patients. As a result, practices can adapt care to better meet patient needs.

References
• https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology
• https://www.cancer.gov/about-cancer/treatment/drugs